Eli Lilly and Company (Lilly) was founded in 1876, with Headquarters located in Indianapolis, Indiana, U.S.A and with operations based in the US and EU, Eli Lilly is now the 10th largest pharmaceutical company in the world. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Eli Lilly is a research-based pharmaceutical company committed to create value for all stakeholders by accelerating the flow of innovative medicines that provide improved outcomes for individual patients and to help people live longer, healthier, more active lives.
Eli Lilly and Company employs approximately 38,000 people worldwide. Approximately 7,400 employees are engaged in research and development. Clinical research is being conducted in more than 55 countries, with research and development facilities located in 8 countries and manufacturing plants located in 13 countries. Lilly products are marketed in 125 countries.
Eli Lilly supports using science-based evaluations to assess and minimize the risks of our pharmaceuticals in the environment. Through collaborations with industry partners, academic researchers, and regulatory agencies, we continually work to further understand and proactively address any potential impacts from the production, distribution, use, and disposal of our products.
Eli-Lilly is active in a variety of international consortia designed to improve the application of safety science to drug safety assessment. Among a longer list of consortium projects, here some highly related with TransQST: MIP-DILI, Disease Drug Model Resources (DDMORE), Safer and Faster Evidence-Based Translation (Safe-T), Comprehensive In vitro Proarrhythimia Assay (CiPA), DILISym Consortium, and SIMCYP Consortium.